Bioinformatics-based prediction of hsa-miR-4651 and hsa-miR-608 as novel biomarkers for diagnosing silicosis.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-06-19 DOI:10.1080/17520363.2025.2520160

Jing Wu, Yimin Shi, Cuiyun Zuo, Yaping Xu, Ying Wu, Haiyan Gong, Yanyan Ke, Xue Yi

{"title":"Bioinformatics-based prediction of hsa-miR-4651 and hsa-miR-608 as novel biomarkers for diagnosing silicosis.","authors":"Jing Wu, Yimin Shi, Cuiyun Zuo, Yaping Xu, Ying Wu, Haiyan Gong, Yanyan Ke, Xue Yi","doi":"10.1080/17520363.2025.2520160","DOIUrl":null,"url":null,"abstract":"Objective: Based on GEO database and bioinformatics to screen silicosis-related differentially expressed genes and analyze the biological functions, in order to provide new ideas and methods for the treatment of silicosis fibrosis.Methods: We predicted microRNAs related to silicosis through bioinformatics and verified the expression of microRNAs in patients with silicosis and healthy people by Real-time Fluorescence Quantitative PCR.Results: Three key genes (LCN2, MMP9, and CCL2) were identified, with hsa-miR-4651, hsa-miR-608, and hsa-miR-3151-5p predicted as their regulatory miRNAs. Hsa-miR-4651 and hsa-miR-608 were significantly upregulated in silicosis patient plasma, indicating their potential as biomarkers for silicosis diagnosis.Conclusions: Hsa-miR-4651 and hsa-miR-608 were identified as potential novel biomarkers for silicosis diagnosis, offering new insights for clinical diagnosis and treatment of silicosis fibrosis.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-11"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2520160","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Based on GEO database and bioinformatics to screen silicosis-related differentially expressed genes and analyze the biological functions, in order to provide new ideas and methods for the treatment of silicosis fibrosis.

Methods: We predicted microRNAs related to silicosis through bioinformatics and verified the expression of microRNAs in patients with silicosis and healthy people by Real-time Fluorescence Quantitative PCR.

Results: Three key genes (LCN2, MMP9, and CCL2) were identified, with hsa-miR-4651, hsa-miR-608, and hsa-miR-3151-5p predicted as their regulatory miRNAs. Hsa-miR-4651 and hsa-miR-608 were significantly upregulated in silicosis patient plasma, indicating their potential as biomarkers for silicosis diagnosis.

Conclusions: Hsa-miR-4651 and hsa-miR-608 were identified as potential novel biomarkers for silicosis diagnosis, offering new insights for clinical diagnosis and treatment of silicosis fibrosis.

查看原文本刊更多论文

基于生物信息学的hsa-miR-4651和hsa-miR-608作为诊断矽肺的新型生物标志物的预测。

目的：基于GEO数据库和生物信息学技术筛选矽肺相关差异表达基因并分析其生物学功能，为矽肺纤维化的治疗提供新的思路和方法。方法：通过生物信息学方法预测与矽肺相关的microrna，并通过实时荧光定量PCR技术验证microrna在矽肺患者和健康人中的表达。结果：三个关键基因（LCN2、MMP9和CCL2）被鉴定出来，hsa-miR-4651、hsa-miR-608和hsa-miR-3151-5p被预测为它们的调节mirna。Hsa-miR-4651和hsa-miR-608在矽肺患者血浆中显著上调，表明它们有可能作为矽肺诊断的生物标志物。结论：Hsa-miR-4651和hsa-miR-608被确定为潜在的新型矽肺诊断生物标志物，为矽肺纤维化的临床诊断和治疗提供新的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.